Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2023-02-08

Last Posted Date: 2024-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 288

Registration Number: NCT05716724

Locations: 🇰🇼
KOC Hospital, Ahmadi, Kuwait
🇸🇦
Al Hammadi, Riyadh, Saudi Arabia
🇸🇦
Dallah Hospital_Riyadh, Riyadh, Saudi Arabia

and more 17 locations

Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Not yet recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2023-02-06

Last Posted Date: 2024-05-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 600

Registration Number: NCT05714683

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Not yet recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2023-01-19

Last Posted Date: 2024-02-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 600

Registration Number: NCT05689372

Awareness, Care & Treatment In Obesity Management

Completed

Conditions: Obesity

Interventions: Other: No treatment given

First Posted Date: 2023-01-19

Last Posted Date: 2023-06-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1688

Registration Number: NCT05690789

Locations: 🇫🇷
Novo Nordisk Investigational Site, Puteaux, France

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Healthy Participants

Interventions: Drug: Semaglutide B, 1.34 mg/mL
Drug: Semaglutide B, 0.68 mg/mL

First Posted Date: 2023-01-18

Last Posted Date: 2024-10-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 20

Registration Number: NCT05689099

Locations: 🇺🇸
Altasciences Clinical LA, Inc., Cypress, California, United States

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)

Phase 3

Active, not recruiting

Conditions: Haemophilia A With Inhibitors
Haemophilia A

Interventions: Drug: Mim8

First Posted Date: 2023-01-17

Last Posted Date: 2024-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 451

Registration Number: NCT05685238

Locations: 🇨🇳
Children's Hospital, Zhejiang University school of medicine, Hangzhou, Zhejiang, China
🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸
UC Denver Hemoph & Thrombo Ctr, Aurora, Colorado, United States

and more 112 locations

A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge

Phase 1

Completed

Conditions: Haemophilia A

Interventions: Drug: NNC0365-3769 (Mim8)

First Posted Date: 2023-01-12

Last Posted Date: 2024-10-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 205

Registration Number: NCT05681845

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Phase 3

Recruiting

Conditions: Cardiovascular Disease

Interventions: Drug: Cagrilintide
Drug: Placebo
Drug: Semaglutide

First Posted Date: 2023-01-03

Last Posted Date: 2024-12-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7000

Registration Number: NCT05669755

Locations: 🇹🇷
Bursa Il Saglik Mudurlugu Yuksek Ihtısas Egitim ve Arastirma Hastanesi, Bursa, Yildirim, Turkey
🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Chambliss Clinical Trials LLC, Montgomery, Alabama, United States

and more 573 locations

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Phase 3

Completed

Conditions: Obesity
Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Semaglutide

First Posted Date: 2022-12-13

Last Posted Date: 2024-12-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 513

Registration Number: NCT05649137

Locations: 🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
John Muir Physicians Network, Concord, California, United States
🇺🇸
Velocity Clinical Research Westlake, Los Angeles, California, United States

and more 64 locations

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

Phase 3

Completed

Conditions: Obesity

Interventions: Drug: Placebo
Drug: Semaglutide

First Posted Date: 2022-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1407

Registration Number: NCT05646706

Locations: 🇨🇦
Premier Clinical Trial Research Network (PCTRN), Hamilton, Ontario, Canada
🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Healthscan Clinical Trials,LLC., Montgomery, Alabama, United States

and more 97 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy